Tirzepatide Trial Targets Type 1 Diabetes and Obesity Management

Individuals with Type 1 Diabetes Mellitus (T1D) often face additional health challenges, including overweight and obesity, which can complicate glycemic control and increase cardiovascular risk. Current treatment strategies primarily focus on insulin management for T1D, but there's a significant unmet need for effective therapies that simultaneously address both T1D and concurrent obesity without exacerbating glycemic variability or increasing hypoglycemia risk.

This Phase 2 study, commencing in December 2026, aims to evaluate whether Tirzepatide can significantly improve metabolic outcomes in this specific patient population. Researchers hypothesize that Tirzepatide, a dual GLP-1 and GIP receptor agonist, will lead to a substantial reduction in HbA1c (a key marker of long-term blood sugar control) and body weight compared to placebo. The trial will quantify changes in daily insulin requirements, time in range (TIR), and other cardiovascular risk factors. The primary objective is to demonstrate a clinically meaningful improvement in glycemic control and body composition, with an anticipated reduction in HbA1c by at least 0.5% and body weight by 5% over the 32-week treatment period. Secondary outcomes will include assessing the percentage change in total daily insulin dose and thoroughly evaluating the safety profile of Tirzepatide in individuals with Type 1 Diabetes.